Monday, March 25, 2013
Although the NASDAQ
Biotechnology Index reached another all-time high last week - a feat almost
unthinkable to anyone who was around during the genomics bubble in 2000 - at
least two buysiders think the market for biotechs still has room to run.
Instead of a sell-off or rotation out of the sector, the performance of the
market cap-weighted NBI could prompt investors to look for buying opportunities
among smaller biotechs.
Prior to this month, the NBI's
previous high was 1,597 on March 6, 2000